Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

Biogen (BIIB) presented data for its Alzheimer’s program that reaffirms a phase II setback, with the drug missing goals. Despite the setback, investors are assessing plans to advance diranersen into phase III, which tempers near-term sentiment. Overall, the update increases uncertainty around timelines and probability of success, keeping risk to the stock elevated.

Analysis

Biogen (BIIB) presented data for its Alzheimer’s program that reaffirms a phase II setback, with the drug missing goals. Despite the setback, investors are assessing plans to advance diranersen into phase III, which tempers near-term sentiment. Overall, the update increases uncertainty around timelines and probability of success, keeping risk to the stock elevated.